Catabasis – Underwritten Registered Offering

Washington, DC – October 7, 2016 – Cooley advised the underwriters on Catabasis Pharmaceuticals’ $11.5 million underwritten registered offering.

Cowen and Company acted as sole book-running manager for the offering.

Catabasis, which trades on The NASDAQ Global Market, is a clinical-stage biopharmaceutical company focused on the discovery and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted (SMART) linker technology platform. Catabasis's SMART linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease.

Cooley advised the underwriters on Catabasis’s $69 million initial public offering in 2015.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brent Siler Partner, Washington, DC
Darren DeStefano Partner, Reston
Div Gupta Partner, New York
Alison Haggerty Associate, New York
Katie Kazem Associate, Reston
Danielle Gershowitz Associate, New York
Natasha Leskovsek Partner, Washington, DC
Wendy Goldstein Partner, New York
Bill Christiansen Partner, Seattle
Francis Wheeler Partner, Colorado
Phil Mitchell Partner, New York
Aaron Nudelman Associate, Seattle